Health IT Analytics March 3, 2021
The effort is part of partnership to accelerate the development of precision medicine therapies for Alzheimer’s disease.
NIH has launched the next version of the Accelerating Medicines Partnership Alzheimer’s disease program (AMP AD 2.0), an effort to enable precision medicine treatments for Alzheimer’s.
AMP AD 2.0 is supporting new technologies, including cutting-edge, single-cell profiling and computational modeling, to facilitate a precision medicine approach to therapy development. The effort is managed through the Foundation for the NIH (FNIH), and brings together NIH, industry, non-profit, and other organizations with the shared goal of using open science practices to accelerate the discovery of new drug targets, biomarkers, and disease subtypes.
“Unraveling the complex biological mechanisms that cause Alzheimer’s disease is critical for therapeutic...
Today's Sponsors
Today's Sponsor